PARUS FINANCE UK Ltd increased its stake in shares of CVS Health Co. (NYSE:CVS - Free Report) by 8.8% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 173,175 shares of the pharmacy operator's stock after buying an additional 14,064 shares during the quarter. CVS Health comprises 7.1% of PARUS FINANCE UK Ltd's holdings, making the stock its 4th largest position. PARUS FINANCE UK Ltd's holdings in CVS Health were worth $13,674,000 as of its most recent filing with the SEC.
A number of other institutional investors have also recently added to or reduced their stakes in the stock. Atticus Wealth Management LLC increased its stake in CVS Health by 149.0% during the fourth quarter. Atticus Wealth Management LLC now owns 366 shares of the pharmacy operator's stock worth $29,000 after acquiring an additional 219 shares during the last quarter. USA Financial Formulas grew its stake in shares of CVS Health by 573.2% in the fourth quarter. USA Financial Formulas now owns 377 shares of the pharmacy operator's stock valued at $30,000 after buying an additional 321 shares in the last quarter. ZRC Wealth Management LLC grew its stake in shares of CVS Health by 400.0% in the fourth quarter. ZRC Wealth Management LLC now owns 500 shares of the pharmacy operator's stock valued at $39,000 after buying an additional 400 shares in the last quarter. Northwest Financial Advisors acquired a new stake in shares of CVS Health in the fourth quarter valued at $42,000. Finally, Coston McIsaac & Partners grew its stake in shares of CVS Health by 42.6% in the fourth quarter. Coston McIsaac & Partners now owns 539 shares of the pharmacy operator's stock valued at $42,000 after buying an additional 161 shares in the last quarter. Hedge funds and other institutional investors own 80.66% of the company's stock.
Insider Buying and Selling
In related news, Director Edward J. Ludwig bought 1,000 shares of CVS Health stock in a transaction that occurred on Thursday, May 2nd. The shares were purchased at an average price of $53.88 per share, with a total value of $53,880.00. Following the purchase, the director now owns 21,630 shares in the company, valued at $1,165,424.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.24% of the company's stock.
CVS Health Stock Performance
NYSE CVS opened at $60.22 on Friday. The stock has a market capitalization of $75.60 billion, a price-to-earnings ratio of 10.58, a PEG ratio of 0.58 and a beta of 0.53. The company has a current ratio of 0.81, a quick ratio of 0.61 and a debt-to-equity ratio of 0.78. The business's 50 day moving average is $61.51 and its two-hundred day moving average is $70.90. CVS Health Co. has a 12-month low of $52.77 and a 12-month high of $83.25.
CVS Health (NYSE:CVS - Get Free Report) last released its quarterly earnings results on Wednesday, May 1st. The pharmacy operator reported $1.31 earnings per share for the quarter, missing analysts' consensus estimates of $1.69 by ($0.38). The firm had revenue of $88.44 billion during the quarter, compared to analyst estimates of $89.33 billion. CVS Health had a return on equity of 13.53% and a net margin of 2.03%. The business's revenue was up 3.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.20 EPS. Research analysts expect that CVS Health Co. will post 7.02 EPS for the current year.
CVS Health Announces Dividend
The company also recently declared a quarterly dividend, which was paid on Wednesday, May 1st. Investors of record on Monday, April 22nd were issued a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.42%. The ex-dividend date of this dividend was Friday, April 19th. CVS Health's dividend payout ratio is currently 46.75%.
Analyst Upgrades and Downgrades
Several research firms recently commented on CVS. Cantor Fitzgerald reissued a "neutral" rating and set a $58.00 target price on shares of CVS Health in a research note on Wednesday. SVB Leerink reissued a "market perform" rating and set a $60.00 target price (down from $87.00) on shares of CVS Health in a research note on Wednesday, May 1st. JPMorgan Chase & Co. lowered their target price on CVS Health from $101.00 to $86.00 and set an "overweight" rating for the company in a research note on Thursday, May 30th. The Goldman Sachs Group lowered their target price on CVS Health from $85.00 to $74.00 and set a "buy" rating for the company in a research note on Thursday, May 2nd. Finally, Baird R W raised CVS Health to a "hold" rating in a report on Thursday, May 30th. Eleven equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat, CVS Health presently has an average rating of "Moderate Buy" and an average target price of $75.05.
Check Out Our Latest Report on CVS Health
CVS Health Profile
(Free Report)
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
Further Reading
- Five stocks we like better than CVS Health
- The Role Economic Reports Play in a Successful Investment Strategy
- Top 5 High-Performance Cryptocurrency ETFs to Watch
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- 3 Stocks That Plummeted After the Post-Fed Speech Crash
- Learn Technical Analysis Skills to Master the Stock Market
- Adobe Stock: It’s Not Too Late To Buy The Dip
→ Claim Your FREE "AI Income Playbook" Now! (From The Oxford Club) (Ad)
Should you invest $1,000 in CVS Health right now?
Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A Guide To High-Short-Interest Stocks
MarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
